Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Research context
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 15.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd's total revenue sank by 16.5% to $338M since the same quarter in the previous year.
Its net income has dropped by 24.6% to $80M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.8% to $75M since the same quarter in the previous year.
Based on the above factors, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd gets an overall score of 2/5.